• Medscape InDiscussion: Moderate to Severe Asthma

  • By: Medscape
  • Podcast

Medscape InDiscussion: Moderate to Severe Asthma

By: Medscape
  • Summary

  • Listen to Medscape InDiscussion: Moderate to Severe Asthma, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987112). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
    Copyright 2023, Medscape
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • S1 Episode 1: Challenges and Opportunities: Precision Medicine in Asthma
    Aug 4 2022

    Listen in as Drs Michael Wechsler and Geoffrey Chupp discuss real-world examples of how they use precision medicine in their own clinics to treat moderate to severe asthma.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969685). The topics and discussions are planned, produced, and reviewed independently of the advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Theophylline (Rx) https://reference.medscape.com/drug/theo-24-theochron-theophylline-343447

    Merged Affinity Network Association Clustering: Joint Multi-Omic/Clinical Clustering to Identify Disease Endotypes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195153/

    How Is the Type 2 (T2 High) Subtype of Asthma? https://www.medscape.com/answers/137501-198413/how-is-the-type-2-t2-high-subtype-of-asthma

    Targeting Interleukins to Treat Severe Asthma https://www.medscape.com/viewarticle/771133_4

    Asthma Workup https://emedicine.medscape.com/article/296301-workup

    ImmunoCAP for IgE-Mediated Hyperreactivity Analysis https://www.bioagilytix.com/immunocap-platform-for-immunogenicity-testing/

    Bronchiectasis https://emedicine.medscape.com/article/296961-overview

    T-Helper Type 2–Driven Inflammation Defines Major Subphenotypes of Asthma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742757/

    Efficacy and Safety of Tralokinumab in Patients With Severe Uncontrolled Asthma: A Randomised, Double-blind, Placebo-Controlled, Phase 2b Trial https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(15)00197-6

    Mepolizumab for Prednisone-Dependent Asthma With Sputum Eosinophilia https://www.nejm.org/doi/full/10.1056/nejmoa0805435

    Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma https://www.nejm.org/doi/full/10.1056/nejmoa0808991

    Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults With Persistent Uncontrolled Asthma (AMAZES): A Randomised, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31281-3/fulltext

    A Randomized, Open-Label, Pragmatic Study to Assess Reliever-Triggered Inhaled Corticosteroid in African American/Black and Hispanic/Latinx Adults With Asthma: Design and Methods of the PREPARE Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130188/

    PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study https://clinicaltrials.gov/ct2/show/NCT04129931

    Show more Show less
    24 mins
  • S1 Episode 2: Precision Medicine and Clinical Trials for Moderate to Severe Asthma: The Past, The Present, and The Future
    Aug 4 2022

    Drs Michael Wechsler and Mario Castro discuss precision medicine for moderate to severe asthma and the past, present, and future of clinical trials.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969686). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) Network https://preciseasthma.org/preciseweb/

    Asthma https://emedicine.medscape.com/article/296301-overview

    The Many 'Buckets' of Severe Asthma: Moving Toward Personalized Managements https://www.jaci-inpractice.org/article/S2213-2198(17)30379-3/pdf

    What is Fractional Exhaled Nitric Oxide (FeNO) in Pulmonary Function Testing?https://www.medscape.com/answers/303239-77907/what-is-fractional-exhaled-nitric-oxide-feno-in-pulmonary-function-testing

    Periostin is a Systemic Biomarker of Eosinophilic Airway Inflammation in Asthmatic Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626285/

    Asthma Workup Approach Considerations https://emedicine.medscape.com/article/296301-workup

    PrecISE: Precision Medicine in Severe Asthma: An Adaptive Platform Trial With Biomarker Ascertainment https://www.jacionline.org/article/S0091-6749(21)00352-3/fulltext

    KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa1613125

    PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study https://clinicaltrials.gov/ct2/show/NCT04129931

    Designing Clinical Trials to Address the Needs Of Childhood And Adult Asthma: The National Heart, Lung, and Blood Institute's AsthmaNet https://www.jacionline.org/article/S0091-6749(13)01638-2/pdf

    Severe Asthma Research Program http://www.severeasthma.org/

    Airways Clinical Research Centers https://www.lung.org/research/airways-clinical-research-centers

    Lung Health Cohort Study: Making History https://www.lung.org/research/lung-health-cohort-study

    Show more Show less
    24 mins
  • S1 Episode 3: Novel Therapies in Severe Asthma Treatment: Precision Medicine, Biomarkers, and New Biologics
    Sep 7 2022

    Drs Wechsler and Akuthota discuss novel therapies in severe asthma treatment, including precision medicine, biomarkers, and new biologic agents.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969688). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Omalizumab https://reference.medscape.com/drug/xolair-omalizumab-343444

    Mepolizumab https://reference.medscape.com/drug/nucala-mepolizumab-1000034

    Bronchial Thermoplasty https://emedicine.medscape.com/article/2094272-overview

    Eosinophilic Asthma and Sputum Eosinophilia https://www.webmd.com/asthma/eosinophilic-asthma-defined

    Role of T2 Inflammation Biomarkers in Severe Asthma https://reference.medscape.com/medline/abstract/26574724

    Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(21)00311-1

    Dupilumab Prescribing Information https://www.regeneron.com/downloads/dupixent_fpi.pdf

    FDA Approves Cinqair to Treat Severe Asthma https://www.fda.gov/news-events/press-announcements/fda-approves-cinqair-treat-severe-asthma

    Benralizumab https://reference.medscape.com/drug/fasenra-benralizumab-1000213

    Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) https://emedicine.medscape.com/article/333492-overview

    Hypereosinophilic Syndrome https://emedicine.medscape.com/article/202030-overview

    Anti-IL-5 Therapy in Patients With Severe Eosinophilic Asthma – Clinical Efficacy and Possible Criteria for Treatment Response https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0689-2

    Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60988-X/fulltext

    Allergic and Environmental Asthma https://emedicine.medscape.com/article/137501-overview

    FDA Approves Maintenance Treatment for Severe Asthma https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma

    Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa2034975

    Efficacy and Safety of Itepekimab in Patients With Moderate-to-Severe Asthma https://www.nejm.org/doi/10.1056/NEJMoa2024257

    The Targeted Eosinophil-Lowering Effects of Dexpramipexole in Clinical Studies https://www.sciencedirect.com/science/article/abs/pii/S107997961630328X

    CRTH2 Antagonists in Asthma: Current Perspectives https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733922

    Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) https://preciseasthma.org/preciseweb/

    A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype https://clinicaltrials.gov/ct2/show/NCT04718389

    Show more Show less
    25 mins

What listeners say about Medscape InDiscussion: Moderate to Severe Asthma

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.